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Abstract: Backgrounds: Investigate whether intraoperative transfusion is a negative prognostic factor for
oncologic outcomes of resected pancreatic cancer. Methods: From June 2004 to January 2014, the medical
records of 305 patients were retrospectively reviewed, who underwent pancreatoduodenectomy, pylorus
preserving pancreatoduodenectomy, total pancreatectomy, distal pancreatectomy for pancreatic cancer.
Patients diagnosed with metastatic disease (n = 3) and locally advanced diseases (n = 15) were excluded
during the analysis, and total of 287 patients were analyzed. Results: The recurrence and disease-specific
survival rates of the patients who received intraoperative transfusion showed poorer survival outcomes
compared to those who did not (P= 0.031,P= 0.010). Through multivariate analysis, T status (HR (hazard
ratio) = 2.04, [95% CI (confidence interval): 1.13–3.68], P= 0.018), N status (HR = 1.46 [95% CI: 1.00–2.12],
P= 0.045), adjuvant chemotherapy (HR = 0.51, [95% CI: 0.35–0.75], P = 0.001), intraoperative transfusion
(HR = 1.94 [95% CI: 1.23–3.07], P = 0.004) were independent prognostic factors of disease-specific
survival after surgery. As well, adjuvant chemotherapy (HR = 0.67, [95% CI: 0.46–0.97], P = 0.035) was
independently associated with tumor recurrence. Estimated blood loss was one of the most powerful
factors associated with intraoperative transfusion (P < 0.001). Conclusions: Intraoperative transfusion
can be considered as an independent prognostic factor of resected pancreatic cancer. As well, it can be
avoided by following strict transfusion policy and using advanced surgical techniques to minimize
bleeding during surgery.
Keywords: transfusion; pancreatic cancer; blood loss; survival rates; intraoperative
1. Background
Pancreatic cancer is an aggressive disease with poor prognosis. Due to its tendency to remain
asymptomatic until it reaches an advanced stage, it is difficult to diagnose and typically deemed unresectable
at the time of diagnosis. When deemed operable, pancreatectomy is considered as the best option in
terms of longer survival [1]. Pancreatectomy in this article refers to all types of curative-intent surgery for
pancreatic cancer which includes pancreatoduodenectomy, pylorus preserving pancreatoduodenectomy,
total pancreatectomy and distal pancreatectomy. However, even when some pancreatic cancers are
discovered at a potentially operable stage, pancreatectomy survival rate is very poor compared to other
types of resected cancers [2].
Factors concerning poor prognosis of pancreatic cancers include high level of CA19-9, large
tumor size, lymph node metastasis, and perineural and lymphovascular invasion [3–6]. However,
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these factors cannot be controlled by surgeons and occur before pancreatectomy is performed. Thus,
instead of examining such uncontrollable prognostic factors, we aim to identify the factors that can be
controlled either at the time of or after surgery. Although adjuvant chemotherapy and radiotherapy
can be performed after surgery, we decided to manipulate the timeline of surgery. Factors such as
availability of combined resection, operation time, amount of blood loss, and availability of transfusion
are decided at the time of surgery and could play a role in improving survival and recurrence
rates of patients who undergo pancreatectomy. Of these factors, we focused on transfusion and
their inappropriate performance during pancreatectomy and hypothesized that reduction of such
inappropriate transfusions could improve patient outcomes [7]. Given that the interactions of the host
immune system and cancer microenvironment play an important role in determining outcome, and
the fact that transfusion lowers a patient’s immunity and aggravates outcome [8,9], we concluded that
intraoperative transfusion (IOT) might lead to poor outcome.
There have been many studies underlining the poor effects of transfusion performed during
pancreatic cancer surgery on patient outcomes. Most, however, focus on the effect of IOT on recurrence
and survival in pancreaticoduodenectomy cases and not in other types of pancreatectomy, because of
the complicated procedure of pancreaticoduodenectomy [10–12]. One particular study suggests that
transfusion performed during pancreatectomy for left-sided pancreatic cancer patients is harmful [7].
While that study focused on more than just pancreaticoduodenectomy, it involved a small number of
subjects and focused only on left-sided pancreatic cancer; therefore, it is unlikely to provide a strong
guideline against transfusion during pancreatic cancer surgery. Thus, we performed our study on
a larger number of subjects and widened the scope to involve all types of pancreatectomy. By doing
so, we hope to provide strong evidence that IOT has a negative effect on the prognosis of patients
undergoing pancreatectomy. The purpose of this study is to investigate the oncologic impact of IOT in
all types of pancreatectomy.
2. Materials and Methods
This study was conducted in accordance with the Declaration of Helsinki and was approved by
the Institutional Review Board of Severance Hospital (registered on 3 March 2019, and registration
number is 2019-0526-001). All patients who underwent pancreatectomy in Severance Hospital of
Yonsei University College of Medicine from June 2004 to January 2014 were enrolled in this study to
evaluate the oncologic impact of IOT in all types of pancreatectomy. Patients diagnosed with metastatic
disease (n = 3) and locally advanced diseases (n = 15) were excluded during the analysis, and total of
287 patients were analyzed. All patients’ medical records were retrospectively reviewed. We analyzed
clinicopathological features, intra-operative findings (including combined resection of other organs
or vascular structures), operation types, neo-adjuvant chemoradiation therapy, TNM (tumor, nodes
and metastases) stage by 8th AJCC classification, postoperative complications, and survival outcomes.
The patients with a pathologic diagnosis of only ductal adenocarcinoma were enrolled, and those with
other pathologic conditions of the pancreas were excluded to create a homogenous patient population.
IOT was defined as any amount of red blood cell transfusion received during the operative procedure.
Details pertaining to the amount of bleeding during operation were evaluated based on operative
medical records. Continuous variables are expressed as mean ± SD (standard deviation), and nominal
variables are expressed as frequency (%). Comparative analysis was performed using the Chi-square
test and Student’s t-test. Survival analysis was calculated using the Kaplan-Meier method, and the
significance of a difference between groups was assessed with a log rank test. Multivariate analysis
was performed to identify risk factors of cancer recurrence and survival rate using a Cox proportional
hazards model. P-values less than 0.05 were considered statistically significant.
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3. Results
3.1. General Characteristics of the Patients
During the study period, 287 patients underwent pancreatectomy for pancreatic ductal adenocarcinoma
(Table 1). The 113 female patients (39.4%) and 174 male patients (60.6%) had an average age of 62.5 ± 9.5 years.
Fifty-seven patients (19.9%) were asymptomatic. Eighty-one patients (28.2%) underwent neo-adjuvant
chemotherapy prior to surgery, while another 206 patients (71.8%) underwent upfront surgery. Seventeen
patients underwent PD (pancreatoduodenectomy) (5.9%), 162 patients underwent PPPD (Pylorus preserving
pancreatoduodenectomy) (56.4%), 101 patients underwent DP (distal pancreatectomy) (35.2%), and 7 patients
underwent TP (Total pancreatectomy) (2.4%). Combined resection was performed in 93 patients (32.4%).
Two hundred and forty-nine patients (86.8%) underwent R0 resection. Post-operative adjuvant chemotherapy
was provided in 211 patients (73.5%). Post-operative mortality occurred in 3 patients (1.0%), and patients with
other complications were assorted according to Clavien-Dindo Classification. It was noted that 69 patients
(24.0%) had IOT (Table 1).
Table 1. General characteristics of the patients.
Variables Value
Age (years) 62.5 ± 9.5
Sex
Female 113 (39.4)
Male 174 (60.6)
Past history
No 75 (26.1)
Yes 212 (73.9)
Symptoms
No 57 (19.9)
Yes 230 (80.1)
Complications (Clavien-Dindo Classification)
None 135 (47.0)
Grade 1 98 (34.1)
Grade 2 17 (5.9)
Grade 3 24 (8.4)
Grade 4 10 (3.5)
Grade 5 3 (1.0)
T status
T0, T1, T2 262 (91.3)
T3, T4 25 (8.7)
N status
N0 137 (47.7)
N1, N2 150 (52.3)
Preoperative CA19_9 719.6 ± 202.7
Neo CRT (Neoadjuvant chemoradiation therapy)
No 206 (71.8)
Yes 81 (28.2)
Adj. CTx (Adjuvant chemotherapy)
No 76 (26.5)
Yes 211 (73.5)
Tumor location
Head 111 (38.7)
Uncinate 66 (23.0)
Neck 6 (2.1)
Body 63 (22.0)
Tail 35 (12.2)
Body + tail 6 (2.1)
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Table 1. Cont.
Variables Value
LVI (Lymphovascular invasion)
No 198 (69.0)
Yes 89 (31.0)
PNI (Perineural invasion)
No 106 (36.9)
Yes 181 (63.1)
Resectability
Resectable 215 (74.9)
Borderline 72 (25.1)
Surgery type
PD 17 (5.9)
PPPD 162 (56.4)
DP 101 (35.2)
TP 7 (2.4)
Operation time (min) 392.6 ± 148.5
Combined resection
No 194 (67.6)
Yes 93 (32.4)
Curative resection
R0 249 (86.8)
R1 34 (11.8)
R2 4 (1.4)
EBL (mL) 654.8 ± 215.5
IOT
No 218 (76.0)
Yes 69 (24.0)
Notes: All data are expressed as mean ± SD or N (%) Abbreviations: PD, pancreatoduodenectomy; PPPD. Pylorus
preserving pancreatoduodenectomy; DP, distal pancreatectomy; TP, Total pancreatectomy; Neo CRT, Neoadjuvant
chemoradiation therapy; Adj. CTx, Adjuvant chemotherapy; LVI, Lymphovascular invasion; PNI, Perineural
invasion; IOT, intraoperative transfusion; and EBL, Estimated blood loss.
3.2. Chronological Trend and Potential Adverse Oncologic Impact of IOT
The incidence of IOT declined significantly during the time period (P = 0.004, Chi-square with
linear-to-linear association, Figure 1). In the early period (2004~2007), 28.6% of the patients (16 out of
56 patients) who underwent radical pancreatectomy for pancreatic cancer received IOT; during the last
period (2012–2014), IOT was performed in only 13.9% of the patients (16 out of 115 patients).
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Figure 1. Trend of IOT (intraoperative transfusion) according to time period.
The disease-specific survival rate of the patients who received IOT showed was significantly
poorer compared to that of the group of patients that did not undergo transfusion during surgery
(median survival of 20 months (95% CI: 18–22) vs. median survival of 33 months (95% CI: 27–38),
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P = 0.010, Figure 2a). The recurrence rate also showed a significant difference between the two groups,
with P = 0.031. The median recurrence interval of patients who underwent IOT was 11 months (95%
CI: 8–13), and that of patients who did not undergo IOT was 12 months (95% CI: 10–15, Figure 2b).
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Figure 2. Long-term oncologic outcomes of resected pancreatic cancer according to IOT (a) represents
the comparison of disease-specific survival rates between the patients who received IOT and those who
did not. (b) represents the comparison of recurrence rates between the patients who received IOT and
those who did not.
3.3. Determining Prognostic Factors in Resected Pancreatic Cancer
In univariate analysis (Table 2), IOT (HR = 1.4 [95% CI: 1.03– .94], P = 0.031) was associated with
tumor recurrence. Also, IOT (HR 1.55 [95% CI: 1.10–2.17], P = 0.0 1), T status (T3&T4, HR = 1.75
[95% CI: 1.04–2.95], P = 0.033), N statu (N1&N2, HR = 1.65 [95% CI: 1.20–2.26], P = 0.002) were
associated with disease-specific survival rate in resected pancreatic cancer.
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Table 2. Prognostic factors in resected pancreatic cancer: Univariate analysis.
Variables
Disease-Specific Survival
(Event = 162)
Recurrence
(Event = 191)
HR (95% CI) P-Value HR (95% CI) P-Value
Age 0.476 0.505
<63 Ref Ref
≥63 1.12 (0.81–1.53) 0.90 (0.68–1.20)
Sex 0.156 0.683
Male Ref Ref
Female 1.36 (0.99–1.88) 1.06 (0.79–1.41)
Past history 0.716 0.741
No Ref Ref
Yes 1.06 (0.75–1.49) 0.94 (0.69–1.30)
Symptoms 0.127 0.118
No Ref Ref
Yes 1.27 (0.93–1.74) 1.24 (0.94–1.67)
Complications 0.28 0.734
None Ref Ref
Grade 1 0.88 (0.63–1.25) 0.94 (0.68–1.29)
Grade 2 0.65 (0.30–1.41) 0.64 (0.32–1.27)
Grade 3 0.45 (0.22–0.89) 0.64 (0.37–1.12)
Grade 4 0.66 (0.27–1.64) 1.32 (0.64–2.73)
Grade 5 1.04 (0.25–4.29) 0.49 (0.06–3.53)
T status 0.033 0.482
T0/T1/T2 Ref Ref
T3/T4 1.75 (1.04–2.95) 1.20 (0.71–2.00)
N status 0.002 0.668
N0 Ref Ref
N1/N2 1.65 (1.20–2.26) 1.05 (0.79–1.40)
Preoperative CA19_9 0.796 0.553
<750 Ref Ref
≥750 1.05 (0.72–1.53) 1.10 (0.78–1.56)
NeoCRT 0.711 0.612
No Ref Ref
Yes 0.96 (0.68–1.36) 1.08 (0.79–1.48)
Adj CTx 0.061 0.082
No Ref Ref
Yes 0.68 (0.49–0.96) 0.86 (0.62–1.19)
Tumor location 0.375 0.824
Head Ref Ref
Uncinate 1.09 (0.71–1.68) 1.04 (0.71–1.51)
Neck 2.66 (1.06–6.68) 2.80 (1.12–7.01)
Body 0.88 (0.58–1.34) 0.71 (0.47–1.05)
Tail 1.61 (1.01–2.57) 1.53 (0.99–2.37)
Body + Tail 0.59 (0.18–1.88) 0.45 (0.14–1.44)
LVI 0.084 0.292
No Ref Ref
Yes 1.33 (0.96–1.84) 1.17 (0.86–1.59)
PNI 0.597 0.393
No Ref Ref
Yes 1.08 (0.79–1.49) 1.13 (0.84–1.52)
Resectability 0.459 0.23
Resectable Ref Ref
Borderline 0.86 (0.59–1.25) 1.21 (0.88–1.67)
Surgery type 0.08 0.202
PD Ref Ref
PPPD 0.58 (0.31–1.06) 1.55 (0.78–3.06)
DP 0.56 (0.30–1.04) 1.23 (0.61–2.50)
TP 1.23 (0.34–4.39) 4.66 (1.72–12.58)
J. Clin. Med. 2020, 9, 689 7 of 12
Table 2. Cont.
Variables
Disease-Specific Survival
(Event = 162)
Recurrence
(Event = 191)
HR (95% CI) P-Value HR (95% CI) P-Value
Operation time 0.778 0.845
<400 Ref Ref
≥400 1.05 (0.73–1.51) 1.03 (0.73–1.45)
Combined resection 0.285 0.07
No Ref Ref
Yes 1.19 (0.86–1.66) 1.31 (0.97–1.77)
Curative resection 0.703 0.765
R0 Ref Ref
R1/R2 1.09 (0.68–1.75) 0.93 (0.59–1.45)
EBL 0.778 0.646
<650 Ref Ref
≥650 1.03 (0.73–1.51) 1.06 (0.80–1.42)
IOT 0.011 0.031
No Ref Ref
Yes 1.55 (1.10–2.17) 1.41 (1.03–1.94)
Period 0.631 0.772
2004–2007 Ref Ref
2008–2011 1.04 (0.71–1.52) 1.05 (0.72–1.54)
2012–2014 0.89 (0.57–1.40) 1.67 (0.72–1.59)
Abbreviations: PD, pancreatoduodenectomy; PPPD. Pylorus preserving pancreatoduodenectomy; DP, distal
pancreatectomy; TP, Total pancreatectomy; Neo CRT, Neoadjuvant chemoradiation therapy; Adj. CTx, Adjuvant
chemotherapy; LVI, Lymphovascular invasion; PNI, Perineural invasion; IOT, intraoperative transfusion; and EBL,
Estimated blood loss.
Multivariate analysis was performed on factors with p-value less than 0.1 in univariate analysis
and was adjusted with the following cofounding factors; IOT, gender, NeoCRT, Adj. CTx, combined
resection, complications, T status, N status, R status, past history, operation time, age, symptoms,
preoperative CA19-9 level, EBL, tumor location, resectability, combined resection, complications,
surgery type, LVI, PNI, and the year surgery was performed. The analysis showed that T status
(HR = 2.04, [95% CI: 1.13–3.68], P = 0.018), N status (HR = 1.46 [95% CI: 1.00–2.12], P = 0.045), Adj.CTx
(HR = 0.51, [95% CI: 0.35–0.75], P = 0.001), IOT (HR = 1.94 [95% CI: 1.23–3.07], P = 0.004), were
independent prognostic factors of disease-specific survival after surgery (Table 3). As well, Adj.CTx
(HR = 0.67, [95% CI: 0.46–0.97], P = 0.035) was independently associated with tumor recurrence
(Table 3).
Table 3. Prognostic factors in resected pancreatic cancer: Multivariate analysis.
Variables
Disease-Specific Survival
(Event = 162)
Recurrence
(Event = 191)
HR (95% CI) P-Value HR (95% CI) P-Value
T status 0.018
T0/T1/T2 Ref
T3/T4 2.04 (1.13–3.68)
N status 0.045
N0 Ref
N1, N2 1.46 (1.00–2.12)
LVI 0.225
No Ref
Yes 1.25 (0.86–1.82)
Surgery type 0.126
PD Ref
PPPD 0.43 (0.20–0.89)
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Table 3. Cont.
Variables
Disease-Specific Survival
(Event = 162)
Recurrence
(Event = 191)
HR (95% CI) P-Value HR (95% CI) P-Value
DP 0.41 (0.13–1.28)
TP 0.97 (0.22–4.25)
Adj.CTx 0.001 0.035
No Ref Ref
Yes 0.51 (0.35–0.75) 0.67 (0.46–0.97)
IOT 0.004 0.056
No Ref Ref
Yes 1.94 (1.23–3.07) 1.47 (0.99–2.20)
Combined
resection 0.727
No Ref
Yes 0.93 (0.64–1.35)
Abbreviations: Adj. CTx, Adjuvant chemotherapy; LVI, Lymphovascular invasion; and IOT, intraoperative transfusion.
3.4. Predicting IOT in Resected Pancreatic Cancer
It was analyzed that combined organ resection (P < 0.001), and EBL (P < 0.001) and the year
surgery was performed (P = 0.004) were significantly related to IOT. Therefore, IOT group correlated
with higher amount of EBL. However, there were no significant differences between age, gender,
past history, symptoms, complications between the group that went through IOT and the group that
did not. (P > 0.05) Additionally, differences between the two groups regarding T status, N status,
M stage, neoadjuvant chemoradiation therapy, adjuvant chemotherapy, tumor location, lymphovascular
invasion, perineural invasion, resectability of tumors, surgery types, operation time, curative resection
between the two groups were also analyzed: there was no differences the two groups. (P > 0.05).
4. Discussion
There have been several studies [13–15] concerning methods to improve surgical outcomes of
resected pancreatic cancer during the past years, though none have achieved great success. The 5-year
survival rate of overall pancreatic cancer is still 9%, and even for the small portion of people who are
diagnosed with localized tumor and deemed operable, the 5-year survival is only 37% which is very
poor compared with other types of tumors [2,16].
Although factors that have an influence on resected pancreatic patient survival and tumor
recurrence rates have been defined by many researchers [3–6,17], there are few studies concerning
factors changeable by surgeons during the intraoperative timeline. Our study showed that T status,
N status, and Adj.CTx were independent prognostic factors associated with tumor recurrence and
disease specific survival rates in resected pancreatic cancer (Table 3). However, the importance of
this study is that IOT can be considered as an independent prognostic factor associated with survival
outcomes of resected pancreatic cancer (P = 0.004, Table 3).
Many studies have revealed the negative effect of blood transfusion on patient survival in
various kinds of resected cancers by showing patients receiving perioperative blood transfusions
have a significantly worse prognosis than patients undergoing cancer surgery without a perioperative
transfusion [18–22]. However, few studies have analyzed the impact of IOT on oncologic outcomes
of pancreatectomy. A previous study reported by Hwang et al. [7] suggested that IOT in left-sided
pancreatic cancer is a prognostic factor associated with tumor recurrence among patients who underwent
pancreatectomy. However, their study focused only on left-sided pancreatic cancer and involved
a relatively small number of subjects. Therefore, it remained controversial whether transfusion has
a detrimental effect on resected pancreatic cancer.
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Although it is hard to argue the idea that IOT is only the aftermath of the large blood loss
which represents tumor’s size and surgery type, combined resection, and patient’s overall health
and not the prognostic factor itself, by using multivariate analysis which was adjusted with many
confounding factors, we were able to prove IOT is an independent prognostic factor of resected
pancreatic cancer. As well, among the factors defined to have an impact on disease-specific survival
of resected pancreatic cancer, IOT was the only factor that can be controlled by surgeons during
the intraoperative period. Since EBL was significantly associated with transfusion during surgery
(P < 0.001, Table 4), we concluded that surgeons should take precautions to reduce bleeding during
pancreatectomy and thereby reduce the chance of IOT. To improve the oncologic outcomes of patients
who undergo pancreatectomy, bleeding should be avoided by applying advanced surgical techniques
based on anatomical knowledge, and inappropriate transfusion should be avoided by following
a strict transfusion policy in consensus with the anesthesiology department. Also, although invasive
pancreatectomy for pancreatic cancer is still controversial, based on the present observation that EBL
was found to be the one of the significant factors contributing to IOT, minimally invasive pancreatectomy
may have potential rationale in managing resectable pancreatic cancer. Many literature reviews and
meta-analysis suggested that laparoscopic and robotic pancreatectomy were strongly associated with
less EBL and less incidence of IOT [23–30].
Table 4. Predicting IOT in resected pancreatic cancer.
Variables
IOT
P-Value
No (n = 218) Yes (n = 69)
Age 0.356
<63 96 (44.0) 26 (37.7)
≥63 122 (56.0) 43 (62.3)
Sex 0.747
Male 87 (39.9) 26 (37.7)
Female 131 (60.1) 43 (62.3)
Past history 0.751
No 58 (26.6) 17 (24.6)
Yes 160 (73.4) 52 (75.4)
Symptoms 0.189
No 53 (24.3) 4 (5.7)
Yes 165 (75.6) 65 (94.3)
Complications 0.293
None 101 (46.3) 34 (49.3)
Grade 1 76 (34.9) 22 (31.9)
Grade 2 11 (5.0) 6 (8.7)
Grade 3 22 (10.1) 2 (2.9)
Grade 4 6 (2.8) 4 (5.8)
Grade 5 2 (0.9) 1 (1.4)
T status 0.638
T0/T1/T2 200 (91.7) 62 (89.9)
T3/T4 18 (8.3) 7 (10.1)
N status 0.285
N0 108 (49.5) 29 (42.0)
N1/N2 110 (50.5) 40 (58.0)
Preoperative CA19_9 0.058
<750 178 (81.7) 49 (71.0)
≥750 40 (18.3) 20 (29.0)
NeoCRT 0.167
No 168 (77.1) 38 (55.1)
Yes 50 (22.9) 31 (44.9)
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Table 4. Cont.
Variables
IOT
P-Value
No (n = 218) Yes (n = 69)
Adj CTx 0.932
No 58 (26.6) 18 (26.1)
Yes 160 (73.4) 51 (73.9)
Tumor location 0.065
Head 74 (33.9) 37 (53.6)
Uncinate 50 (22.9) 20 (23.2)
Neck 6 (2.8) 0 (0.0)
Body 50 (22.9) 13 (18.8)
Tail 32 (14.7) 3 (4.3)
Body + Tail 6 (2.8) 0 (0.00)
LVI 0.276
No 146 (67.0) 52 (75.4)
Yes 72 (33.0) 17 (24.6)
PNI 0.674
No 78 (35.8) 28 (40.6)
Yes 140 (64.2) 41 (59.4)
Resectability 0.651
Resectable 175 (80.3) 40 (58.0)
Borderline 43 (19.7) 29 (42.0)
Surgery type
PD 13 (6.0) 4 (5.8)
PPPD 114 (52.3) 48 (69.6)
DP 87 (39.9) 14 (20.3)
TP 4 (1.8) 3 (4.3)
Operation time 0.064
<400 123 (56.4) 14 (20.3)
≥400 95 (43.6) 55 (79.7)
Combined resection <.0.001
No 167 (76.6) 27 (39.1)
Yes 51 (23.4) 42 (60.9)
Curative resection 0.641
R0 188 (86.2) 61 (88.4)
R1/R2 30 (13.8) 8 (11.6)
EBL <0.001
<650 145 (66.5) 10 (14.5)
≥650 73 (33.5) 59 (85.5)
Period 0.004
2004–2007 40 (18.3) 16 (23.2)
2008–2011 79 (36.2) 37 (53.6)
2012–2014 99 (45.4) 16 (23.2)
Abbreviations: PD, pancreatoduodenectomy; PPPD. Pylorus preserving pancreatoduodenectomy; DP, distal
pancreatectomy; TP, Total pancreatectomy; Neo CRT, Neoadjuvant chemoradiation therapy; Adj. CTx, Adjuvant
chemotherapy; LVI, Lymphovascular invasion; PNI, Perineural invasion; IOT, intraoperative transfusion; and EBL,
Estimated blood loss.
However, our present study has several limitations. Firstly, our study was a single-center, retrospective
study with a limited number of patients. If the study was conducted with more subjects in multi-center,
the results would have been more powerful. Hence, further research is needed. By using broad clinical data
from Korean multicenter research and Korea-Japan joint research, more powerful evidence for prognosis of
transfusion in resected pancreatic cancer could be made. Also, through prospective cohort study of strict
transfusion policy, a comparative study using propensity score matching can be envisioned. Secondly,
our study failed to support an association between tumor recurrence and IOT. Although a Kaplan-Meier
curve (P = 0.031, Figure 2b) and univariate analysis showed that IOT was strongly associated with tumor
recurrence (P = 0.031, Table 2), subsequent multivariate analysis indicated that IOT is not accurately
associated with tumor recurrence in resected pancreatic cancer (P = 0.056, Table 3). Again, with study
J. Clin. Med. 2020, 9, 689 11 of 12
conducted with more subjects in multi-center, the result may indicate IOT as a prognostic factor for
tumor recurrence.
In summary, IOT was strongly associated with poorer survival outcomes of resected pancreatic
cancer. Although the trend of performing IOT on resected pancreatic cancer is declining, more strict
actions should be applied to achieve better outcomes. IOT is thought to be a controllable factor that
can be managed, and it can be achieved not only by improving surgical technique such as minimal
invasive surgery, but also by implementing an intraoperative transfusion guideline in cooperation
with the anesthesiologic department.
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